Shanghai Xuerong Biotechnology Co (300511) Fair Value & Analysis
Consumer Defensive · CN · Market cap 3.6B CNY
Fair value as of: Jul 9, 2026
From 24 valuation models · updated 32 days ago
Share price −5.0% over the past month.
Below-average quality, and screening another 63% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥2.59). The favourable scenario is already priced in.
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥1.16 to ¥2.59) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥2.46 – ¥11.44 · fair‑value band ¥1.16 – ¥2.59 · the ¥5.27 price screens above the ¥1.97 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Shanghai Xuerong Biotechnology Co (300511) currently trades at ¥5.27, while our model-based Fair Value estimate is ¥1.97, implying the stock looks roughly 62.6% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shanghai Xuerong Biotechnology Co generated revenue of 2.2B CNY at a net margin of 8.8%. Revenue grew 54.1% year over year. It earns a return on equity of 14.6%. Net debt stands at 915M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥1.16 (bear case) to ¥2.59 (bull case); at ¥5.27, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at 102% fair-value upside, at -63%, 300511 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (¥4.98) versus Earnings-Based (¥0.3400). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai Xuerong Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research and development, cultivation and sale of fresh edible mushrooms in the People's Republic of China.
Full company description
Shanghai Xuerong Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research and development, cultivation and sale of fresh edible mushrooms in the People's Republic of China. It offers enoki mushrooms; shiitake mushrooms, including oyster mushrooms, white jade mushrooms and seafood mushrooms; king oyster mushrooms; and velvet mushrooms, as well as Pleurotus eryngii and Flammulina velutipes. The company was formerly known as Shanghai Gaorong Food Co., Ltd. Shanghai Xuerong Biotechnology Co., Ltd. was founded in 1997 and is headquartered in Shanghai, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Xuerong Biotechnology Co reported revenue of ¥2.0B in FY2025 versus ¥2.1B in FY2021, a compound −0.9%/yr. Reported net income was ¥29.8M in FY2025.
300511 screens 63% overvalued. Compare with Muyuan Foods Group →
Peer Group
Farm Products · 291 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Farm Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Farm Products stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Muyuan Foods Group 002714 | ¥40.90 | ¥48.19 | +18% |
| Wens Foodstuff Group 300498 | ¥14.51 | ¥12.08 | -17% |
| Mowi ASA MOWI | kr 188.40 | kr 262.59 | +39% |
| PT Charoen Pokphand Indonesia Tbk, CPIN | 3,120 IDR | 7,076 IDR | +127% |
| Charoen Pokphand Foods Public Company CPF | 22.00 THB | 55.71 THB | +153% |
| PT Triputra Agro Persada Tbk TAPG | 1,540 IDR | 3,105 IDR | +102% |
| PT FAP Agri Tbk FAPA | 7,300 IDR | 7,463 IDR | +2% |
| PT Japfa Comfeed Indonesia Tbk JPFA | 2,070 IDR | 7,231 IDR | +249% |
| Thaifoods Group TFGR | 10.60 THB | 23.53 THB | +122% |
| PT Jhonlin Agro Raya Tbk JARR | 1,845 IDR | 610.80 IDR | -67% |
Compare Shanghai Xuerong Biotechnology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Shanghai Xuerong Biotechnology Co (300511) overvalued or undervalued?
What is the fair value of 300511?
What is the quality score of 300511?
What is the revenue of Shanghai Xuerong Biotechnology Co (300511)?
What is the net profit margin of 300511?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai Xuerong Biotechnology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.